 |
Lab Rats to UnicornsLRTU Author: John Flavin
Lab Rats to Unicorns is a podcast that aims to demystify the process of creating a great company in life sciences. Under the guidance of our host, John Flavin, you will hear personal stories of creation, be able to understand how great companies are created, and get insights into the many ways that you as an individual can engage in the creation of tomorrows life science companies. From the lab rat, signifying the process of invention and discovery, to the unicorn, signifying market success, there are a thousand players and ways in which people can contribute to the creation of great companies. Language: en Genres: Business, Entrepreneurship, Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
Science, Policy & the FDA with Robert Califf_e.081
Episode 81
Wednesday, 11 March, 2026
In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Robert Califf, physician-scientist and two-time Commissioner of the U.S. Food and Drug Administration under Presidents Barack Obama and Joe Biden. A cardiologist by training and longtime leader in clinical research, Dr. Califf has spent his career at the intersection of medicine, technology, regulation, and public service. From founding the Duke Clinical Research Institute to guiding the FDA through the COVID-19 pandemic, Dr. Califf brings a rare perspective on how science becomes medicine—and how policy, politics, and evidence shape what ultimately reaches patients. He reflects on the early days of cardiology breakthroughs, the birth of large-scale clinical trials, and the responsibility regulators carry in balancing innovation with safety. The conversation explores translational medicine, the realities of uncertainty in public health, the evolving role of AI in healthcare, and the global competition shaping the future of biomedical innovation. At its core, this episode is about decision-making under pressure—and the systems required to ensure that groundbreaking ideas translate into measurable benefit for patients.
